Publications by authors named "S Champiat"

Claim this Profile
A
ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC).
M Roupret, A Bertaut, G Pignot, Y Neuzillet, N Houede, S Champiat

Ann Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multi-institutional perspective on tarlatamab administration and management of CRS/ICANS.
Bingnan Zhang, Laura Alder, Samuel Rosner, Aakash Desai, Alissa J Cooper, Stephane Champiat

Lung Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond Proton Pump Inhibitors: Evaluating Treatment Strategies for Immune-Mediated Gastroenteritis from Cancer Immunotherapy.
Carolina Colli Cruz, Maria Julia Moura Nascimento Santos, Sharada Wali, Cristina Natha, Rachel Mortan, Stephane Champiat

Target Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From toxicity assessment to adaptive safety care: implementing comprehensive fast-track safety evaluation for anticancer drug development.
S Champiat, K Ouali, A Laparra, A Charalambous, M Di Palma

ESMO Open· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockade.
Romain Guitton, Ariane Laparra, Noemie Chanson, Stephane Champiat, Francois-Xavier Danlos

J Immunother Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis